NEWARK, Del., March 4, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) announced it is proceeding with development of an antibody candidate as a therapeutic against influenza, including highly pathogenic H5N1 strains resistant to drugs such as oseltamivir (marketed as Tamiflu®). This proprietary antibody, which is based upon iBio's iBioLaunch™ technology, has demonstrated safety and therapeutic efficacy in highly predictive animal models infected with a variety of influenza types, including H5N1.
The influenza antibody was discovered by scientists at Fraunhofer USA Center for Molecular Biotechnology (Fraunhofer) and is a part of Bio's successful antibody research collaboration with Fraunhofer. Prior to the discovery of this influenza antibody product candidate, the collaboration has produced rituximab and palivizumab biosimilar candidates.
"We are pleased to further expand our antibody product candidate pipeline, particularly with an important proprietary candidate," said Robert Kay, Chairman and CEO of iBio. "This development continues our strategy to grant royalty-bearing licenses of iBioLaunch technology to others for development of their products using our platform, as we recently announced with Caliber Biotherapeutics for their anti-cancer monoclonal antibody candidate, while we continue to bring forward our own product candidates for self-development and eventual partnership with others."About the iBioLaunch™ Platform The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems may include: success with proteins difficult or impossible to produce with other methods; broad applicability to biologics, including therapeutic proteins and vaccines; production time measured in weeks instead of months or more. Additional benefits may include a surge capacity for remedial action against bioterrorism and pandemic disease including influenza; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV